Adynxx, Inc. (ADYX) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 San Francisco, CA, 美国. 现任CEO为 Richard Orr.
ADYX 拥有 IPO日期为 1998-12-18, 6 名全职员工, 在 Other OTC, 市值为 $581.00.
Adynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. The company was founded in 2007 and is headquartered in San Francisco, California.
